Cargando…

A simplified mesoscale 3D model for characterizing fibrinolysis under flow conditions

One of the routine clinical treatments to eliminate ischemic stroke thrombi is injecting a biochemical product into the patient’s bloodstream, which breaks down the thrombi’s fibrin fibers: intravenous or intravascular thrombolysis. However, this procedure is not without risk for the patient; the wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Petkantchin, Remy, Rousseau, Alexandre, Eker, Omer, Zouaoui Boudjeltia, Karim, Raynaud, Franck, Chopard, Bastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444897/
https://www.ncbi.nlm.nih.gov/pubmed/37608073
http://dx.doi.org/10.1038/s41598-023-40973-1
_version_ 1785094057163227136
author Petkantchin, Remy
Rousseau, Alexandre
Eker, Omer
Zouaoui Boudjeltia, Karim
Raynaud, Franck
Chopard, Bastien
author_facet Petkantchin, Remy
Rousseau, Alexandre
Eker, Omer
Zouaoui Boudjeltia, Karim
Raynaud, Franck
Chopard, Bastien
author_sort Petkantchin, Remy
collection PubMed
description One of the routine clinical treatments to eliminate ischemic stroke thrombi is injecting a biochemical product into the patient’s bloodstream, which breaks down the thrombi’s fibrin fibers: intravenous or intravascular thrombolysis. However, this procedure is not without risk for the patient; the worst circumstances can cause a brain hemorrhage or embolism that can be fatal. Improvement in patient management drastically reduced these risks, and patients who benefited from thrombolysis soon after the onset of the stroke have a significantly better 3-month prognosis, but treatment success is highly variable. The causes of this variability remain unclear, and it is likely that some fundamental aspects still require thorough investigations. For that reason, we conducted in vitro flow-driven fibrinolysis experiments to study pure fibrin thrombi breakdown in controlled conditions and observed that the lysis front evolved non-linearly in time. To understand these results, we developed an analytical 1D lysis model in which the thrombus is considered a porous medium. The lytic cascade is reduced to a second-order reaction involving fibrin and a surrogate pro-fibrinolytic agent. The model was able to reproduce the observed lysis evolution under the assumptions of constant fluid velocity and lysis occurring only at the front. For adding complexity, such as clot heterogeneity or complex flow conditions, we propose a 3-dimensional mesoscopic numerical model of blood flow and fibrinolysis, which validates the analytical model’s results. Such a numerical model could help us better understand the spatial evolution of the thrombi breakdown, extract the most relevant physiological parameters to lysis efficiency, and possibly explain the failure of the clinical treatment. These findings suggest that even though real-world fibrinolysis is a complex biological process, a simplified model can recover the main features of lysis evolution.
format Online
Article
Text
id pubmed-10444897
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-104448972023-08-24 A simplified mesoscale 3D model for characterizing fibrinolysis under flow conditions Petkantchin, Remy Rousseau, Alexandre Eker, Omer Zouaoui Boudjeltia, Karim Raynaud, Franck Chopard, Bastien Sci Rep Article One of the routine clinical treatments to eliminate ischemic stroke thrombi is injecting a biochemical product into the patient’s bloodstream, which breaks down the thrombi’s fibrin fibers: intravenous or intravascular thrombolysis. However, this procedure is not without risk for the patient; the worst circumstances can cause a brain hemorrhage or embolism that can be fatal. Improvement in patient management drastically reduced these risks, and patients who benefited from thrombolysis soon after the onset of the stroke have a significantly better 3-month prognosis, but treatment success is highly variable. The causes of this variability remain unclear, and it is likely that some fundamental aspects still require thorough investigations. For that reason, we conducted in vitro flow-driven fibrinolysis experiments to study pure fibrin thrombi breakdown in controlled conditions and observed that the lysis front evolved non-linearly in time. To understand these results, we developed an analytical 1D lysis model in which the thrombus is considered a porous medium. The lytic cascade is reduced to a second-order reaction involving fibrin and a surrogate pro-fibrinolytic agent. The model was able to reproduce the observed lysis evolution under the assumptions of constant fluid velocity and lysis occurring only at the front. For adding complexity, such as clot heterogeneity or complex flow conditions, we propose a 3-dimensional mesoscopic numerical model of blood flow and fibrinolysis, which validates the analytical model’s results. Such a numerical model could help us better understand the spatial evolution of the thrombi breakdown, extract the most relevant physiological parameters to lysis efficiency, and possibly explain the failure of the clinical treatment. These findings suggest that even though real-world fibrinolysis is a complex biological process, a simplified model can recover the main features of lysis evolution. Nature Publishing Group UK 2023-08-22 /pmc/articles/PMC10444897/ /pubmed/37608073 http://dx.doi.org/10.1038/s41598-023-40973-1 Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Petkantchin, Remy
Rousseau, Alexandre
Eker, Omer
Zouaoui Boudjeltia, Karim
Raynaud, Franck
Chopard, Bastien
A simplified mesoscale 3D model for characterizing fibrinolysis under flow conditions
title A simplified mesoscale 3D model for characterizing fibrinolysis under flow conditions
title_full A simplified mesoscale 3D model for characterizing fibrinolysis under flow conditions
title_fullStr A simplified mesoscale 3D model for characterizing fibrinolysis under flow conditions
title_full_unstemmed A simplified mesoscale 3D model for characterizing fibrinolysis under flow conditions
title_short A simplified mesoscale 3D model for characterizing fibrinolysis under flow conditions
title_sort simplified mesoscale 3d model for characterizing fibrinolysis under flow conditions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444897/
https://www.ncbi.nlm.nih.gov/pubmed/37608073
http://dx.doi.org/10.1038/s41598-023-40973-1
work_keys_str_mv AT petkantchinremy asimplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions
AT rousseaualexandre asimplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions
AT ekeromer asimplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions
AT zouaouiboudjeltiakarim asimplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions
AT raynaudfranck asimplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions
AT chopardbastien asimplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions
AT asimplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions
AT petkantchinremy simplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions
AT rousseaualexandre simplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions
AT ekeromer simplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions
AT zouaouiboudjeltiakarim simplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions
AT raynaudfranck simplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions
AT chopardbastien simplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions
AT simplifiedmesoscale3dmodelforcharacterizingfibrinolysisunderflowconditions